Characterisation of factor IX with a glycine-to-valine missense mutation at residue 190 in a patient with severe haemophilia B

Summary

A patient with severe haemophilia B with a glycine-to-valine missense mutation at residue 190 (c25, chymotrypsin numbering) in factor IX (FIX; FIX-G190V or FIX-FuChou) had <1% of normal FIX clotting activity and 36% of normal FIX antigen levels (cross-reacting material-reduced, CRM^r). Residue 190 in the C-terminal protease domain of human FIX is highly conserved in mammalian species and the serine protease family, suggesting that it has an indispensable role in protein function. To explore the pathological mechanism by which this mutation contributes to dysfunction of the FIX molecule, we functionally characterised FIX-G190V in vitro and in vivo. Liver-specific FIX-G190V gene expression following hydrodynamic plasmid delivery into haemophilia B mice revealed a 5.7-fold reduction in specific clotting activity compared with FIX-WT (wild type) and a two-fold decrease in plasma FIX-G190V concentration. Pulse-chase analysis demonstrated that FIX-G190V was secreted at a significantly slower rate than was FIX-WT. Purified FIX-G190V and FIX-WT displayed normal calcium-dependent conformational changes as shown by intrinsic fluorescence quenching. The in vivo half-lives of FIX-G190V and FIX-WT were indistinguishable. FIX-G190V was, however, more readily degraded than FIX-WT, especially after being activated by the active form of FXI. The vulnerable sites were mapped to the peptide bonds at Arg¹¹⁶-Leu¹¹⁷, Lys²⁶⁵-Tyr²⁶⁶, Arg³²⁷-Val³²⁸, and Arg³³⁸-Ser³³⁹, which are in the exposed loops of the FIX molecule. Also, failure of FXIa-activated FIX-G190V to bind p-aminobenzamidine indicated an abnormal conformation of the active-site pocket. Thus, the mutation at residue 190 of FIX may result in protein misfolding that affects secretion, clotting function, and hydrolysis.

Keywords

Factor IX - haemophilia B - cross-reacting material-reduced

• References

• 1 Hoffman R. Hematology : basic principles and practice. 4th ed. Elsevier Churchill Livingstone; 2005
• 2 White 2nd GC, Rosendaal F, Aledort LM. et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
• 3 Yoshitake S, Schach BG, Foster DC. et al. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 1985; 24: 3736-3750.
• 4 Jackson CM, Nemerson Y. Blood coagulation. Annu Rev Biochem 1980; 49: 765-811.
• 5 Nelsestuen GL, Broderius M, Martin G. Role of gamma-carboxyglutamic acid. Cation specificity of prothrombin and factor X-phospholipid binding. J Biol Chem 1976; 251: 6886-6893.
• 6 Chang YJ, Wu HL, Hamaguchi N. et al. Identification of functionally important residues of the epidermal growth factor-2 domain of factor IX by alanine-scanning mutagenesis. Residues Asn(89)-Gly(93) are critical for binding factor VIIIa. J Biol Chem 2002; 277: 25393-25399.
• 7 Wu PC, Hamaguchi N, Yu YS. et al. Hemophilia B with mutations at glycine-48 of factor IX exhibited delayed activation by the factor VIIa-tissue factor complex. Thromb Haemost 2000; 84: 626-634.
• 8 Gailani D. Activation of factor IX by factor XIa. Trends Cardiovasc Med 2000; 10: 198-204.
• 9 Jesty J, Silverberg SA. Kinetics of the tissue factor-dependent activation of coagulation Factors IX and X in a bovine plasma system. J Biol Chem 1979; 254: 12337-12345.
• 10 Brandstetter H, Bauer M, Huber R. et al. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci USA 1995; 92: 9796-9800.
• 11 Lawson JH, Mann KG. Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem 1991; 266: 11317-11327.
• 12 Monroe DM, Sherrill GB, Roberts HR. Use of p-aminobenzamidine to monitor activation of trypsin-like serine proteases. Anal Biochem 1988; 172: 427-435.
• 13 Lin SW, Shen MC. Characterization of genetic defects of hemophilia B of Chinese origin. Thromb Haemost 1991; 66: 459-463.
• 14 Lin SW, Shen MC. Genetic basis and carrier detection of hemophilia B of Chinese origin. Thromb Haemost 1993; 69: 247-252.
• 15 Thompson AR. Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B. J Clin Invest 1977; 59: 900-910.
• 16 Furie B, Bing DH, Feldmann RJ. et al. Computer-generated models of blood coagulation factor Xa, factor IXa, and thrombin based upon structural homology with other serine proteases. J Biol Chem 1982; 257: 3875-3882.
• 17 Lin SW, Smith KJ, Welsch D. et al. Expression and characterization of human factor IX and factor IX-factor X chimeras in mouse C127 cells. J Biol Chem 1990; 265: 144-150.
• 18 Andersson S, Davis DL, Dahlback H. et al. Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J Biol Chem 1989; 264: 8222-8229.
• 19 Lin HF, Maeda N, Smithies O. et al. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997; 90: 3962-3966.
• 20 Miao CH, Thompson AR, Loeb K. et al. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Ther 2001; 3: 947-957.
• 21 Lin CN, Kao CY, Miao CH. et al. Generation of a novel factor IX with augmented clotting activities in vitro and in vivo. J Thromb Haemost. 2010 prepublished online.
• 22 Jin DY, Zhang TP, Gui T. et al. Creation of a mouse expressing defective human factor IX. Blood 2004; 104: 1733-1739.
• 23 Enjolras N, Plantier JL, Rodriguez MH. et al. Two novel mutations in EGF-like domains of human factor IX dramatically impair intracellular processing and secretion. J Thromb Haemost 2004; 2: 1143-1154.
• 24 Southern PJ, Berg P. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet 1982; 1: 327-341.
• 25 Lin SW, Lin CN, Hamaguchi N. et al. Characterization of a factor IX variant with a glycine207 to glutamic acid mutation. Blood 1994; 84: 1866-1873.
• 26 Kao CY, Lin CN, Yu IS. et al. FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis. Thromb Haemost 2010; 104: 355-365.
• 27 Giannelli F, Green PM, Sommer SS. et al. Haemophilia B: database of point mutations and short additions and deletions--eighth edition. Nucleic Acids Res 1998; 26: 265-268.
• 28 Hallgren KW, Hommema EL, McNally BA. et al. Carboxylase overexpression effects full carboxylation but poor release and secretion of factor IX: implications for the release of vitamin K-dependent proteins. Biochemistry 2002; 41: 15045-15055.
• 29 Schmidt AE, Bajaj SP. Structure-function relationships in factor IX and factor IXa. Trends Cardiovasc Med 2003; 13: 39-45.
• 30 Hoffman M, Monroe DM. 3rd. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-965.
• 31 Perera L, Darden TA, Pedersen LG. Modeling human zymogen factor IX. Thromb Haemost 2001; 85: 596-603.
• 32 Lind B, Gedde-Dahl T, Tjonnfjord G. et al. Protein C deficiency caused by homozygosity for a novel PROC D180G mutation--in vitro expression and structural analysis of the mutation. Thromb Haemost 2002; 88: 632-638.
• 33 Akhavan S, Miteva MA, Villoutreix BO. et al. A critical role for Gly25 in the B chain of human thrombin. J Thromb Haemost 2005; 3: 139-145.
• 34 Deane CM, Allen FH, Taylor R. et al. Carbonyl-carbonyl interactions stabilize the partially allowed Ramachandran conformations of asparagine and aspartic acid. Protein Eng 1999; 12: 1025-1028.
• 35 Kisiel W, Smith KJ, McMullen BA. Proteolytic inactivation of blood coagulation factor IX by thrombin. Blood 1985; 66: 1302-1308.